In summary, treatment interruption or early discontinuation of trastuzumab therapy in early HER2-positive BC is associated with worse DFS and OS irrespective of age, receptor status, stage of disease and treatment-induced cardiotoxicity. Here, ERBB2 is linked to breast cancer.